Artegraft Collagen Vascular Graft
LeMaitre Vascular, Inc. · Decision date Sep 4, 2026
What did the FDA approve?
FDA recorded approval of supplement N16837/S039 for LeMaitre Vascular, Inc.'s Artegraft Collagen Vascular Graft, a tissue graft of 6mm and greater under product code LXA in the cardiovascular specialty. The supplement is a Special (Immediate Track) submission with a stated reason of labeling change covering indications, instructions, shelf life, or tradename. As a supplement to the original PMA, it is not a new approval of the whole device system.
The source statement describes the approved change as a new warning and other labeling changes in the Instructions for Use. It does not identify the specific wording of the warning, which other labeling items changed, or the original PMA's initial scope. The stated purpose is the labeling change itself, not independent proof of safety or clinical effectiveness, and no such findings are reported in the supplied fields.
FDA approval order statement
Approval of a new warning and other labeling changes in the Instructions for Use for the Artegraft Collagen Vascular Graft
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 4, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- N16837/S039
- Regulatory pathway
- PMA supplement
- Applicant
- LeMaitre Vascular, Inc.
- Product code
- LXA
- Decision code
- APPR
- Decision date
- Sep 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Tissue graft of 6mm and greater.
- Applicant
- LeMaitre Vascular, Inc.
- Product code
- LXA
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
N16837/S039 received
Application receipt date recorded by FDA.
N16837/S039 · FDA decision
Special (Immediate Track)
Related devices and submissions
Explore the linked device profile
Other records with product code LXA
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Artegraft Collagen Vascular GraftN16837/S040 | LeMaitre Vascular, Inc. | PMA supplement | Oct 15, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
LeMaitre Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 63 Second Ave., Burlington, MA, 01803
Sources and methodology
- Original FDA record: N16837/S039
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records